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Abstract–A convenient and unequivocal synthesis of the title compounds from isoselenocyanates, 
malononitrile or 2-cyanoacetate, and 1,2-dibromoethane or α-halogenated carboxylic acid derivatives is 
reported. The proposed reaction mechanism involves in situ cyclization of different halogenated 
compounds with an intermediate keten-N,Se-acetal, generated by the base promoted nucleophilic 
addition of the acidic cyanomethylenes to aliphatic and aromatic isoselenocyanates. Chemical and 
spectroscopic evidence for the structures of the new compounds is presented. 
 
 
 
 
1. Introduction 
 
The explosive growth of the interest in organoselenium chemistry over the past twenty-five years can be 
attributed to the specific properties of organic selenium compounds, which fit into the requirements of 
modern organic synthesis. Most of them are well adapted to chemo-, regio-, and stereoselective 
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reactions.2 In particular, selenium-containing heterocyclic compounds have been well recognized not 
only because of their remarkable reactivities and chemical properties,3 but also because of their diverse 
pharmaceutical applications.4 For this reason we are interested in the use of isoselenocyanates 1 in 
heterocyclic synthesis.5 They are useful starting materials, since they are easy to prepare6 and are safe to 
handle and store. In addition, they typically react under mild conditions, which are compatible with the 
low stability of substrates and products in the preparation of complex molecules. 
 
Several reviews7 have described the preparation and pharmaceutical potential of 1,3-selenazoles.8 They 
have been studied in diverse areas of interest, for example as antitumor9 and antiradiation agents,10 
enzyme inhibitors,11 antifilarial12 and antiviral compounds,13 delivery agents,14 and prodrugs of 
selenocysteine,15 and are also well recognized in the chemistry of dyes.16  
 
For the reaction of isoselenocyanates with nucleophiles it is known that nitrogen, oxygen, sulfur, and 
selenium nucleophiles add to the central carbon atom,17 whereas phosphorus nucleophiles attack either 
the central carbon atom or the selenium atom.18 Although only a few examples of the reaction of 
isoselenocyanates with carbon nucleophiles have been described, it was recently reported that suitable 
carbanions and isoselenocyanates can produce selenium-containing compounds.19 To the best of our 
knowledge, only one paper describes such a reaction being used for the synthesis of 1,3-selenazoles.20 
On the other hand, 1,3-selenazolidinones have been prepared from different starting materials, such as 
isothiocyanates,21 selenazadienes,22 and widely from selenoureas,23 but never with isoselenocyanates. 
For this reason, we have investigated the use of isoselenocyanates 1, which are conveniently prepared by 
Barton’s procedure,6 as building blocks in the synthesis of selenaheterocycles and heterocyclic 
selones.24-35 For example, it has been shown that the reactions of bifunctional nucleophiles 2 with 1 yield 
five to seven-membered heterocycles of type 4 and 5 (Scheme 1). A likely intermediate is the adduct 3, 
which undergoes the ring closure by nucleophilic substitution of the leaving group X either by the Se or 
the N-atom. As a continuation of previous work, we decided to investigate the addition of carbon 
nucleophiles with 1 and to trap the intermediate by a suitably substituted electrophilic reagent.  
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Scheme 1. 
 
2. Results and discussion 
 
After several unsuccessful attempts at reactions of isoselenocyanates with β-diketons like acetylacetone 
and dibenzoylmethane, we were successful by using cyanomethylene derivatives. Malononitrile and 
ethyl cyanoacetate react at room temperature with aryl and alkyl isoselenocyanates in the presence of a 
base to afford an intermediate keten-N,Se-acetal 7, which subsequently can react with different 
halogenated compounds (Scheme 2). 
 
 
 
Scheme 2. 
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For example, the carbanion obtained from malononitrile (6a) and triethylamine in DMF added to 
isoselenocyanates 1 to give an intermediate of type 7. The latter reacted with 1,2-dibromoethane (8) to 
give another intermediate 9, which cyclized to yield 1,3-selenazolidine derivatives of type 10. After 
stirring for four hours, the reaction mixture was evaporated to dryness and the residue was purified by 
column chromatography on silica gel and recrystallization from ethyl acetate (Table 1). Similar reactions 
were performed starting with ethyl cyanoacetate (6b). It is worth mentioning that only one isomer was 
obtained in the case of the cyanoacetates 10e-g (Table 1). 
  
The structures of the products were established on the basis of their spectroscopic data and, in the cases 
of 10a and 10c, by X-ray crystallography (Figure 1). The 2-(1,3-selenazolidin-2-ylidene)malononitriles 
10a-d show two different CN absorptions in the IR spectra (KBr; ca. 2203 and 2190 cm-1) and 13C NMR 
spectra (DMSO; ca. 112 and 118 ppm). For the 2-cyano-2-(1,3-selenazolidin-2-yliden)acetates 10e-g, 
the CN absorption appears at ca. 2195 cm-1 and 114 ppm.  
 
Table 1. Preparation of 1,3-selenazolidines 10 from isoselenocyanates 1 
 
Entry R1  Y  1,3-Selenazolidines 10 Yield (%) 
 
a 
 
Phenyl 
 
CN 
NC CN
N Se
 
 
62 
 
b 
 
4-F-C6H4 
 
CN 
NC CN
N Se
F
 
 
54 
 
c 
 
4-MeO-C6H4 
 
CN 
NC CN
N Se
MeO
 
 
61 
 
d 
 
Cyclohexyl 
 
CN 
NC CN
N Se
 
 
42 
 
e 
 
Phenyl 
 
CO2Et 
NC CO2Et
N Se
 
 
31 
5 
 
f 
 
4-F-C6H4 
 
CO2Et 
NC CO2Et
N Se
F
 
 
36 
 
g 
 
4-Me-C6H4 
 
CO2Et 
NC CO2Et
N Se
Me
 
 
31 
 
In the crystal structure of 10a, the two CH2 groups in the five-membered ring are disordered over two 
approximately equally occupied positions, which result from alternate half-chair puckering of the ring 
conformation. The two cyano groups are coplanar with the atoms Se(1),C(2),N(3), and C(6), but the 
bond angles at the dicyanomethylidene C-atom are significantly different: whereas the angles C(2)-C(6)-
C(7) and C(7)-C(6)-C(8) are small (118.2(1) and 115.7(1)°, resp.), the angle C(2)-C(6)-C(8) is widened 
(126.1(2)°), i.e. the CN group is tilted away from the phenyl residue. In turn, the latter is twisted out of 
the plane above mentioned by ca. 86°. Furthermore, the CN group pointing toward the phenyl residue is 
slightly bent away from the phenyl ring (N(8)-C(8)-C(6) = 175.2(2)°) whereas the other one is linear 
(N(7)-C(7)-C(6) = 179.3(2)°. In the case of 10c, the five-membered ring has a half-chair conformation 
twisted on C(4)-C(5). The other structure parameters of 10c are very similar to those of 10a. 
 
a) b) 
     
 
Figure 1. ORTEP plot36 of the molecular structure of a) the major conformation of 10a and b) of 10c 
(arbitrary numbering of atoms; 50% probability ellipsoids). 
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The analogous reaction of 1, 6a, and methyl 2-chloroacetate (11a) gave the 2-(4-oxo-1,3-selenazolidin-
2-ylidene)malononitriles of type 13 (Scheme 2, Table 2). We propose that 12 is the intermediate, which 
is the product of the reaction of the initially formed 7 with the halogenated compound. A subsequent 
condensation by elimination of methanol then yields 13. In the case of 13a and13d, the same products 
were obtained in increased yield by using ethyl bromoacetate (11b). Furthermore, the reaction with 
methyl 2-chloropropionate 11c led to the 5-methyl derivatives 13h and 13i (Table 2). 
 
As in the case of the malononitriles 10a-d, the 4-oxo derivatives of type 13 show two CN absorptions in 
the IR (ca. 2220 and 2210 cm-1) and in the 13C NMR spectrum (ca. 110 and 115 ppm). In addition, the 
CO group appears at 1733-1743 cm-1 and 160-173 ppm. The structure of 13a was established by X-ray 
crystallography (Figure 2). Although the compound is achiral, it has crystallized in a polar space group 
and the absolute structure has been determined by the diffraction experiment. The five-membered ring is 
almost planar, but is puckered slightly towards an envelope conformation where atom C(5) lies 0.149(2) 
Å from the mean plane defined by the other four ring atoms. The adjacent atoms O(4) and C(9), as well 
as the dicyanomethylidene group, are also lying in this ring plane. The phenyl group is oriented almost 
orthogonal to the above defined heterocyclic ring plane (dihedral angle ca. 86°). The other structure 
parameters are very similar to those of 10a and 10c. 
 
 
Table 2. Preparation of 1,3-selenazolidin-4-ones 13 from isoselenocyanates 1 
 
Entry R1 Acetate  1,3-Selenazolidin-4-ones 13 Yield (%) 
 
a 
 
Phenyl 
MeO2C Cl    11a 
EtO2C Br    11b 
BrOC Br    14a 
NC CN
N Se
O  
74 
81 
85 
 
b 
 
4-F-C6H4 
 
BrOC Br    14a 
NC CN
N Se
O
F
 
 
83 
 
c 
 
4-Cl-C6H4 
 
MeO2C Cl    11a 
NC CN
N Se
O
Cl
 
 
68 
7 
 
d 
 
4-Br-C6H4 
MeO2C Cl    11a 
EtO2C Br    11b 
NC CN
N Se
O
Br
 
87 
95 
 
e 
 
4-MeO-C6H4 
 
BrOC Br    14a 
NC CN
N Se
O
MeO
 
 
74 
 
f 
 
2,6-DiMe-C6H3 
 
BrOC Br    14a 
NC CN
N Se
O  
 
83 
 
g 
 
Cyclohexyl 
MeO2C Cl    11a 
BrOC Br    14a 
NC CN
N Se
O  
34 
33 
 
h 
 
Phenyl MeO2C Cl
Me
   11c 
NC CN
N Se
O Me  
 
63 
 
i 
 
4-Me-C6H4 MeO2C Cl
Me
   11c 
BrOC Br
Me
   14b 
NC CN
N Se
Me
O Me  
 
89 
63 
 
k 
 
Phenyl 
 
MeO2C Cl    11a 
NC CO2Et
N Se
O  
 
64 
 
l 
 
4-Br-C6H4 
 
MeO2C Cl    11a 
NC CO2Et
N Se
Br
O  
 
86 
 
m 
 
4-Me-C6H4 
 
MeO2C Cl    11a 
NC CO2Et
N Se
Me
O  
 
78 
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Figure 2. ORTEP plot36 of the molecular structure of 13a (arbitrary numbering of atoms; 50% 
probability ellipsoids). 
 
The corresponding ethyl 2-cyano-2-(4-oxo-1,3-selenazolidin-2-yliden)acetates 13k-m were prepared in 
a similar manner from 1, 6b, and 11a (Scheme 2, Table 2). Again, only one isomer was obtained (TLC, 
NMR). In the case of 13k, the molecular structure was established by X-ray crystallography (Figure 3). 
The exocyclic C,C-double bond is (Z)-configured, i.e., the sterically more demanding ester group is 
pointing away from the N-phenyl group. There are two symmetrically-independent molecules in the 
asymmetric unit. One of these molecules (A) has disorder in the terminal ethyl group of the ester 
substituent, with the major conformation being present in ca. 58% of the molecules. Molecules A and B 
have almost identical conformations with the only significant conformational difference being a small 
rotation in the orientation of the terminal ethyl group. The five-membered heterocyclic rings deviate 
only slightly from perfect planarity with the maximum deviation from the mean plane of the ring in 
molecule B being 0.032(2) Å for atom C(22). The ring in molecule A has a flattened envelope 
conformation puckered on atom Se(1), where Se(1) lies 0.204(1) Å from the mean plane defined by the 
other four ring atoms. 
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Figure 3. ORTEP plot36 of the molecular structure of the major conformation of molecule A of 13k 
(arbitrary numbering of atoms; 50% probability ellipsoids). 
 
Treatment of the intermediates 7 with bromoacetyl bromide (14a) led to a surprising result. As the 
reaction between thioureas and acyl halides is known to give S-acylated isothioureas,37 we expected that 
7 and 14a would give 15 by the reaction of the more nucleophilic Se-atom with the more electrophilic 
acyl C-atom (Scheme 3). Under the basic reaction conditions, the subsequent cyclization via 
nucleophilic substitution of bromide by the N-atom could lead to the 5-oxo-1,3-selenazolidine 
derivatives 16, which are isomers of 13. Mohareb,38 Bukowski,39 and more recently Metwally and 
coworkers,40 described analogous reactions with isothiocyanates, which led to 1,3-thiazolidin-5-ones. 
On the other hand, Koketsu et al.41 reported the synthesis of 1,3-selenazolidine-4-ones from selenourea 
and α-haloacyl halides. Although NMR analysis should differentiate clearly between the two isomeric 
structures, some doubts about the structures remain. 
 
The reaction of 1a with 6a and 14a under the usual conditions led to a single product in 85% yield, 
which was identified as 13a by direct comparison with the product obtained from the reaction with 11a. 
Analogously, only one product was formed in all the other reactions of 1 with 6a,b and 14a. By 
comparison of their 1H and 13C NMR spectra with those of 13a, we attributed the structures 13b, 13e, 
13f, and 13g to these products (Table 2). Furthermore, the product 13g obtained from cyclohexyl 
isoselenocyanate, malononitrile (6a), and 2-bromoacetyl bromide (14a) was in all respects identical with 
10 
13g formed in the reaction with methyl 2-chloroacetate. With 4-methylphenyl isoselenocyanate, 6a, and 
2-bromopropanoyl bromide (14b), 13i was obtained in 63% yield (Table 2). 
 
The unexpected formation of the 4-oxo-1,3-selenazolidine derivatives 13 in the reactions with 2-
bromoacetyl bromide 14a can be explained by the reaction mechanism shown in Scheme 4. The 
intermediate 15, which is formed by the nucleophilic substitution of the acyl bromide of 14a by the Se-
atom of 7 undergoes a base catalyzed 1,3-acyl shift to give the rearranged intermediate 17. Similar S → 
N migrations of the acetyl group are known and have been studied in depth kinetically42 and described 
recently by Pihlaja and coworkers.43 Finally, the Se-atom attacks the α-carbon atom of the amide group 
and forms the 1,3-selenazolidinone ring by displacing the bromide ion to give 13.  
 
 
 
Scheme 3. 
 
Another goal of the present study was the synthesis of analogous 1,3-selenazolidin-4,5-diones. In the 
first instance, we tried to trap 7 with oxalyl chloride, but we did not succeed in obtaining the dioxo 
derivatives. Furthermore, all attempts to use diethyl oxalate or the recently described ethyl 2-chloro-
oxoacetate44 were also unsuccessful. In addition, the oxidation of 13a by selenium dioxide45 failed to 
give the corresponding 1,3-selenazolidine-4,5-dione. 
 
 
3. Conclusion 
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In conclusion, we have shown that malononitrile (6a) and alkyl 2-cyanoacetates (6b,c) react with 
isoselenocyanates 1 in DMF in the presence of excess triethylamine to give intermediates 7, which react 
with 1,2-dibromoethane or α-halogenated acyl derivatives to give 1,3-selenazolidines 10 and 1,3-
selenazolidin-4-ones 13, respectively, in moderate to good yields. This one-pot reaction offers a 
convenient access to these selenium-containing five-membered heterocycles by starting with  
isoselenocyanates 1 as building blocks. 
 
 
4. Experimental Part 
 
4.1. General  
 
Thin layer chromatography (TLC): silica gel 60 F254 plates (0.25 mm; Merck). Column chromatography 
(CC): silica gel 60 (0.040-0.063 mm; Merck). Mp: Büchi B-540 apparatus in capillary tubes; 
uncorrected. IR Spectra: Perkin–Elmer-1600 FT-IR spectrophotometer; in KBr; absorptions in cm–1. 1H-
NMR (300 MHz) and 13C-NMR (75.5 MHz) Spectra: Bruker ARX-300 instrument; in (D6)DMSO 
unless otherwise stated; chemical shifts (δ) in ppm; couplig constants J in Hz. CI-MS: Finnigan SSQ-
700 or MAT-90 instrument; NH3 as carrier gas. 
 
Starting materials. Malononitrile (6a) and all halogenated compounds are commercially available 
(Fluka). Isoselenocyanates (1) were prepared according to Barton’s procedure6 by starting from 
formamides. Formanilide and N-cyclohexylformamide were purchased (Fluka and Aldrich), N-(4-
chlorophenyl)-, N-(4-bromophenyl)-, N-(4-fluorophenyl)-, and N-(4-methoxyphenyl)formamide were 
prepared from the respective anilines and 95% formic acid (ref.46). The solution was heated to reflux for 
30 min and then evaporated to dryness in vacuo. The residue was dissolved in ether and washed with 
diluted acetic acid (5%), water, and aqueous NaHCO3 (5%). The aqueous layer was extracted with ether, 
the combined organic extracts were dried over MgSO4, and evaporated under reduced pressure. The 
crude products were purified by recrystallization in water. 
 
General Procedure for the preparation of 1,3-selenazolidine derivatives. A 25 mL round-bottom flask 
equipped with a magnetic stirrer and condenser was charged with a solution of malononitrile (6a; 73 mg, 
12 
1.1 mmol) in DMF (10 mL). Triethylamine (0.15 mL, 1.1 mmol) was added and the mixture was stirred 
for 30 min at rt. Isoselenocyanate (1; 1.1 mmol) was added and the mixture was stirred for 1 h at rt. 
Then, the α-halogenated compound (1.1 mmol) was added dropwise and the mixture was stirred for 4 h 
before being evaporated to dryness under reduced pressure. The crude product was purified by column 
chromatography on silica gel with hexane/ethyl acetate (100/0 to 50/50) as eluant and recrystallized 
from ethyl acetate. 
 
4.2. Preparation of 2-methylene-1,3-selenazolidines 10 
 
4.2.1. 2-(3-Phenyl-1,3-selenazolidin-2-ylidene)malononitrile (10a). Yield: 187 mg (62%). Yellowish 
crystals. Mp 295–297 °C. IR: 2935w, 2205s, 2191s, 1594w, 1527s, 1492m, 1453w, 1432w, 1388m, 
1310m, 1238w, 1220w, 1064w, 1057w, 759w, 691m. 1H-NMR: 3.49 (t, J = 7.1, CH2), 4.46 (t, J = 7.1, 
CH2), 7.31 (d-like, J = 8.2, 2 arom. H), 7.46–7.51 (m, 3 arom. H). 13C-NMR: 22.2 (CH2), 51.8 (C(CN)2), 
64.6 (CH2), 112.0 (CN), 117.7 (CN), 126.4 (2 CH), 129.8 (CH), 129.9 (2 CH), 138.9 (Car), 171.9 
(CNSe). ESI-MS: 298 (100, [M(80Se)+Na]+), 276 (22, [M(80Se)+1]+). Anal. calcd for C12H9N3Se 
(274.19): C 52.57, H 3.31, N 15.33; found: C 52.54, H 3.49, N 15.41. 
Suitable crystals for the X-ray crystal structure determination were grown from CH2Cl2 by slow 
evaporation of the solvent. 
 
4.2.2. 2-[3-(4-Fluorophenyl)-1,3-selenazolidin-2-ylidene]malononitrile (10b). Yield: 174 mg (54%). 
White crystals. Mp 193–195 °C. IR: 2985w, 2202s, 2191s, 1535s, 1505s, 1453w, 1394w, 1319w, 
1236w, 1214m, 1054w, 846w. 1H-NMR: 3.54 (t, J = 7.1, CH2), 4.42 (t, J = 7.1, CH2), 7.27 (t-like, J ≈ 
8.9, 2 arom. H), 7.50 (dd-like, J ≈ 9.0, 4.9, 2 arom. H). 13C-NMR: 23.6 (CH2), 51.1 (C(CN)2), 65.5 
(CH2), 113.1 (CN), 117.4 (d, 2JCF = 22, 2 CH), 118.7 (CN), 129.7 (d, 3JCF = 9, 2 CH), 141.9 (Car), 167.4 
(d, 1JCF = 248, CF), 173.7 (CNSe). CI-MS: 311 (100, [M(80Se)+NH4]+), 294 (7, [M(80Se)+1]+). 
 
4.2.3. 2-[3-(4-Methoxyphenyl)-1,3-selenazolidin-2-ylidene]malononitrile (10c). Yield: 205 mg 
(61%). Yellowish crystals. Mp 187–189 °C. IR: 2939w, 2839w, 2203s, 2190s, 1607w, 1587w, 1539s, 
1509w, 1474m, 1443w, 1391s, 1319m, 1299m, 1246s, 1171w, 1109w, 1056w, 1026m, 985w, 864w, 
831m, 803w. 1H-NMR: 3.47 (t, J = 7.1, CH2), 3.83 (s, CH3), 4.40 (t, J = 7.1, CH2), 6.96, 7.21 (AA'BB', 
JAB ≈ 8.2, 4 arom. H). 13C-NMR: 22.0 (CH2), 51.2 (C(CN)2), 55.5 (CH3O), 64.8 (CH2), 112.2 (CN), 
115.0 (2 CH), 118.0 (CN), 127.8 (2 CH), 131.4 (Car), 160.5 (Car), 172.2 (CNSe). CI-MS: 323 (100, 
13 
[M(80Se)+NH4]+), 306 (8, [M(80Se)+1]+). Anal. calcd for C13H11N3OSe (304.21): C 51.33, H 3.64, N 
13.81; found: C 51.22, H 3.62, N 13.77. 
Suitable crystals for the X-ray crystal structure determination were grown from CH2Cl2 by slow 
evaporation of the solvent. 
 
4.2.4. 2-(3-Cyclohexyl-1,3-selenazolidin-2-ylidene)malononitrile (10d). Yield: 130 mg (42%). 
Yellowish crystals. Mp 187–189 °C. IR: 2937s, 2850m, 2202s, 2188s, 1527s, 1457m, 1396w, 1372m, 
1350w, 1308w, 1241w, 1192w, 1124w, 1010w, 982w, 893w, 879w, 823w. 1H-NMR: 1.40–1.52 (m, 4 
H), 1.60–1.70 (m, 2 H), 1.75–1.98 (m, 4 H), 3.26 (t, J = 7.1, CH2), 4.13 (t, J = 7.1, CH2) 4.35–4.45 (m, 
CH). 13C-NMR: 21.7 (CH2), 24.8 (2 CH2), 24.9 (CH2), 31.4 (2 CH2), 48.0 (C(CN)2), 55.6 (CH), 59.4 
(CH2), 115.1 (CN), 118.3 (CN), 171.4 (CNSe). CI-MS: 299 (100, [M(80Se)+NH4]+), 282 (7, 
[M(80Se)+1]+). Anal. calcd for C12H15N3Se (280.23): C 51.43, H 5.40, N 15.00; found: C 51.33, H 5.45, 
N 14.88. 
 
4.2.5. Ethyl 2-cyano-2-(3-phenyl-1,3-selenazolidin-2-ylidene)acetate (10e). Yield: 110 mg (31%). 
Yellowish crystals. Mp 151–153 °C. IR: 2969w, 2195s, 1668s, 1595w, 1512s, 1458m, 1431w, 1392m, 
1367w, 1283s, 1254w, 1187w, 1172m, 1023w, 921w, 763m, 695m. 1H-NMR: 1.27 (t, J = 7.1, CH3), 
3.10 (t, J = 7.2, CH2), 4.21 (q, J = 7.2, CH2), 4.28 (t, J = 7.1, CH2), 7.26 (d-like, J ≈ 8.2, 2 arom. H), 
7.40–7.49 (m, 3 arom. H). 13C-NMR: 14.3 (CH3), 20.0 (CH2), 61.1 (CH2), 62.5 (CH2), 73.3 (C(CN)), 
114.6 (CN), 126.5 (2 CH), 128.9 (CH), 129.6 (2 CH), 141.3 (Car), 167.6 (CO2), 171.6 (CNSe). CI-MS: 
340 (100, [M(80Se)+NH4]+), 323 (53, [M(80Se)+1]+). Anal. calcd for C14H14N2O2Se (321.24): C 52.35, H 
4.39, N 8.72; found: C 51.98, H 4.46, N 8.70. 
 
4.2.6. Ethyl 2-cyano-2-[3-(4-fluorophenyl)-1,3-selenazolidin-2-ylidene]acetate (10f). Yield: 135 mg 
(36%). Yellowish crystals. Mp 162–164 °C.  IR: 3048w, 2976m, 2878w, 2190s, 1671s, 1603m, 1510s, 
1454s, 1432m, 1387s, 1365m, 1288s, 1234m, 1221m, 1191w, 1171w, 1117s, 1057w, 1029w, 995m, 
918m, 845s, 767s, 735w, 717w. 1H-NMR: 1.28 (t, J = 7.1, CH3), 3.11 (t, J = 7.2, CH2), 4.19–4.27 (m, 2 
CH2), 7.11–7.17 (m, 2 arom. H), 7.23–7.29 (m, 2 arom. H). 13C-NMR: 14.3 (CH3), 19.9 (CH2), 61.2 
(CH2), 62.5 (CH2), 73.1 (C(CN)), 114.5 (CN), 116.7 (d, 2JCF = 23, 2 CH), 128.4 (d, 3JCF = 9, 2 CH), 
137.2 (Car), 163.4 (d, 1JCF = 256, CF), 167.5 (CO2), 171.9 (CNSe). CI-MS: 358 (100, [M(80Se)+NH4]+), 
341 (33, [M(80Se)+1]+). 
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4.2.7. Ethyl 2-cyano-2-[3-(4-methylphenyl)-1,3-selenazolidin-2-ylidene)acetate (10g). Yield: 115 mg 
(31%). Yellowish crystals. Mp 144–146 °C. IR: 2982w, 2918w, 2198s, 1669s, 1511s, 1392m, 1370w, 
1287s, 1192w, 1170m, 1129s, 1058w, 1029w, 921w, 766m. 1H-NMR: 1.27 (t, J = 7.1, CH3), 2.39 (s, 
CH3), 3.09 (t, J = 7.2, CH2), 4.18–4.28 (m, 2 CH2), 7.15, 7.25 (AA'BB', JAB ≈ 8.1, 4 arom. H). 13C-
NMR: 14.3 (CH3), 19.9 (CH2), 21.2 (CH3), 61.1 (CH2), 62.6 (CH2), 73.1 (C(CN)), 114.6 (CN), 126.2 (2 
CH), 130.2 (2 CH), 138.8 (Car), 139.0 (Car), 167.7 (CO2), 171.6 (CNSe). CI-MS: 354 (100, 
[M(80Se)+NH4]+), 337 (43, [M(80Se)+1]+). Anal. calcd for C15H16N2O2Se (335.26): C 53.74, H 4.81, N 
8.36; found: C 53.60, H 5.01, N 8.43. 
 
4.3. Preparation of 2-methylene-1,3-selenazolidin-4-ones 13 
 
4.3.1. 2-(4-Oxo-3-phenyl-1,3-selenazolidin-2-ylidene)malononitrile (13a). Yield: 235–270 mg (74–
85%). Colorless crystals. Mp 265–267 °C. IR: 2985w, 2216s, 1733s, 1596w, 1522s, 1493m, 1368m, 
1223s, 851w, 758w, 698m. 1H-NMR: 4.39 (s, CH2), 7.43 (d-like, J ≈ 7.9, 2 arom. H), 7.50–7.60 (m, 3 
arom. H). 13C-NMR: 29.1 (CH2), 56.7 (C(CN)2), 110.1 (CN), 115.1 (CN), 128.9 (2 CH), 129.4 (2 CH), 
130.8 (CH), 134.8 (Car), 173.3, 173.9 (CO, CNSe). CI-MS: 307 (100, [M(80Se)+NH4]+); CI-MS (i-
butane): 290 (100, [M(80Se)+1]+). Anal. calcd for C12H7N3OSe (288.16): C 50.02, H 2.45, N 14.58; 
found: C 49.98, H 2.60, N 14.34. 
Suitable crystals for the X-ray crystal structure determination were grown from CH2Cl2 by slow 
evaporation of the solvent. 
 
4.3.2. 2-[3-(4-Fluorophenyl)-4-oxo-1,3-selenazolidin-2-ylidene]malononitrile (13b). Yield: 280 mg 
(83%). Colorless crystals. M.p. 244–246 °C. IR: 2995w, 2982w, 2219s, 2210s, 1737s, 1600w, 1528s, 
1516s, 1507s, 1373m, 1222s, 1208s, 1161w, 858w, 826w, 791w. 1H-NMR: 4.65 (s, CH2), 7.67 (t-like, J 
≈ 9, 2 arom. H), 7.49–7.59 (m, 2 arom. H). 13C-NMR: 29.0 (CH2), 56.7 (C(CN)2), 110.2 (CN), 114.9 
(CN), 116.4 (d, 2JCF = 23, 2 CH), 131.1 (Car), 131.5 (d, 3JCF = 9, 2 CH), 163.2 (d, 1JCF = 248, CF), 173.7, 
173.9 (CO, CNSe). CI-MS: 325 (100, [M(80Se)+NH4]+). Anal. calcd for C12H6N3OSeF (306.16): C 
47.08, H 1.98, N 13.73; found: C 47.01, H 2.21, N 14.02. 
 
4.3.3. 2-[3-(4-Chlorophenyl)-4-oxo-1,3-selenazolidin-2-ylidene]malononitrile (13c). Yield: 242 mg 
(68%). Colorless crystals. Mp 245–247 °C. IR: 2947w, 2223m, 2213m, 1733s, 1529s, 1485m, 1404w, 
1370m, 1219s, 1172w, 1084w, 1015w, 845w, 813w, 722w. 1H-NMR: 4.33 (s, CH2), 7.45, 7.58 (AA'BB', 
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JAB ≈ 8.7, 4 arom. H). 13C-NMR: 29.1 (CH2), 56.7 (C(CN)2), 110.3 (CN), 114.9 (CN), 129.5 (2 CH), 
131.0 (2 CH), 133.7 (Car), 135.5 (Car), 173.4, 173.8 (CO, CNSe). CI-MS: 341 (100, [M(80Se, 
35Cl)+NH4]+). Anal. calcd for C12H6N3OSeCl (322.61): C 44.68, H 1.87, N 13.03; found: C 44.75, H 
2.10, N 12.92. 
 
4.3.4. 2-[3-(4-Bromophenyl)-4-oxo-1,3-selenazolidin-2-ylidene]malononitrile (13d). Yield: 351–383 
mg (87–95%). Colorless crystals. Mp 247–249 °C. IR: 2947w, 2222s, 2211s, 1736s, 1585w, 1526s, 
1481s, 1399w, 1371m, 1218s, 1171m, 1066w, 1012m, 842m, 809m, 711w. 1H-NMR: 4.67 (s, CH2), 
7.71, 8.05 (AA'BB', JAB ≈ 8.7, 4 arom. H). 13C-NMR: 29.1 (CH2), 56.8 (C(CN)2), 110.3 (CN), 114.9 
(CN), 129.5 (2 CH), 131.0 (2 CH), 133.7 (Car), 135.6 (Car), 173.4, 173.8 (CO, CNSe). CI-MS: 387 (79, 
[M(80Se, 81Br)+NH4]+), 385 (100, [M(80Se, 79Br)+NH4]+). Anal. calcd for C12H6N3OSeBr (367.07): C 
39.27, H 1.65, N 11.45; found: C 39.44, H 1.86, N 11.49. 
 
4.3.5. 2-[3-(4-Methoxyphenyl)-4-oxo-1,3-selenazolidin-2-ylidene]malononitrile (13e). Yield: 259 mg  
(74%). Orange crystals. Mp 193–195 °C. IR: 2945w, 2216m, 2210m, 1752m, 1606w, 1523s, 1508s, 
1369m, 1303w, 1255m, 1212m, 1015w, 822w. 1H-NMR: 3.83 (s, CH3O), 4.38 (s, CH2), 7.07, 7.35 
(AA'BB', JAB ≈ 8.0, 4 arom. H). 13C-NMR: 28.9 (CH2), 55.4 (CH3), 56.6 (C(CN)2), 110.2 (CN), 114.6 (2 
CH), 115.1 (CN), 127.3 (Car), 130.2 (2 CH), 132.4 (Car), 160.8 (CO), 173.9 (CNSe). CI-MS: 337 (100, 
[M(80Se)+NH4]+). Anal. calcd for C13H9N3O2Se (318.20): C 49.07, H 2.85, N 13.21; found: C 48.84, H 
3.01, N 13.57. 
 
4.3.6. 2-[3-(2,6-Dimethylphenyl)-4-oxo-1,3-selenazolidin-2-ylidene]malononitrile (13f). Yield: 289 
mg (83%). Colorless crystals. Mp 296–298 °C. IR: 3000w, 2944w, 2217s, 2206s, 1742s, 1517s, 1474m, 
1392w, 1352s, 1217m, 1205s, 1183m, 1151m, 1035w, 837w, 785m, 736w. 1H-NMR: 2.16 (s, 2 CH3), 
4.72 (s, CH2), 7.28 (d, J = 7.8, 2 arom. H), 7.44 (t, J = 7.9, 1 arom. H). 13C-NMR: 16.7 (2 CH3), 28.7 
(CH2), 57.1 (C(CN)2), 109.3 (CN), 114.7 (CN), 128.3 (2 CH), 130.9 (CH), 132.4 (Car), 136.5 (2 Car), 
171.5, 173.3 (CO, CNSe). CI-MS: 335 (100, [M(80Se)+NH4]+). Anal. calcd for C14H11N3OSe (316.22): 
C 53.18, H 3.51, N 13.29; found: C 53.18, H 3.58, N 13.03. 
 
4.3.7. 2-(3-Cyclohexyl-4-oxo-1,3-selenazolidin-2-ylidene)malononitrile (13g). Yield: 107–110 mg 
(33–34%). Brownish crystals. Mp 123–125 °C. IR: 2996w, 2942s, 2855m, 2217m, 2206m, 1738s, 
1701w, 1573m, 1507s, 1448m, 1400w, 1335m, 1254w, 1202m, 1193m, 1179m, 1141m, 1052w, 980w, 
16 
895w, 696m. 1H-NMR: 1.23–1.54 (m, 4 H), 1.71–1.90 (m, 4 H), 2.27–2.40 (m, 2 H), 3.98 (s, CH2), 
4.51–4.61 (m, CH). 13C-NMR: 24.4 (CH2), 24.8 (2 CH2), 28.7 (2 CH2), 32.2 (CH), 59.4 (C(CN)2), 61.7 
(CH), 112.0 (CN), 114.3 (CN), 170.1 (CO), 173.5 (CNSe). CI-MS: 313 (100, [M(80Se)+NH4]+). Anal. 
calcd for C12H13N3OSe (294.21): C 48.99, H 4.45, N 14.28; found: C 50.23, H 4.54, N 14.40. 
 
4.3.8. 2-(5-Methyl-4-oxo-3-phenyl-1,3-selenazolidin-2-ylidene)malononitrile (13h). Yield: 210 mg 
(63%). White crystals. Mp 173–175 °C. IR: 2961w, 2217m, 2202m, 1735s, 1593w, 1518s, 1493m, 
1363m, 1266w, 1222s, 1069w, 996w, 940w, 763w, 728w, 697w. 1H-NMR: 1.94 (d, J = 7.3, CH3), 4.55 
(q, J = 7.3, CH), 7.26 (d, J = 8.1, 2 arom. H), 7.54–7.63 (m, 3 arom. H). 13C-NMR: 19.4 (CH3), 38.7 
(CH), 61.6 (C(CN)2), 109.3 (CN), 113.8 (CN), 128.6 (2 CH), 130.1 (CH), 131.6 (2 CH), 134.3 (Car), 
167.4 (CO), 176.3 (CNSe). CI-MS: 321 (100, [M(80Se)+NH4]+). Anal. calcd for C13H9N3OSe (302.19): 
C 51.67, H 3.00, N 13.91; found: C 51.50, H 4.10, N 14.15. 
 
4.3.9. 2-[5-Methyl-3-(4-methylphenyl)-4-oxo-1,3-selenazolidin-2-ylidene)malononitrile (13i). Yield: 
220–310 mg (63–89%). White crystals. Mp 223–225 °C. IR: 2933w, 2216m, 2208m, 1741s, 1521s, 
1216s, 1160w, 1071w, 996w, 814w, 771w, 734w. 1H-NMR: 1.92 (d, J = 7.3, CH3), 2.44 (s, CH3), 4.53 
(q, J = 7.2, CH), 7.10, 7.35 (AA'BB', JAB ≈ 8.1, 4 arom. H). 13C-NMR: 19.4 (CH3), 21.4 (CH3), 38.6 
(CH), 61.6 (C(CN)2), 109.3 (CN), 113.9 (CN), 128.2 (2 CH), 130.7 (2 CH), 131.6 (Car), 142.2 (Car), 
167.5 (CO), 176.4 (CNSe). CI-MS: 335 (100, [M(80Se)+NH4]+). Anal. calcd for C14H11N3OSe (316.22): 
C 53.18, H 3.51, N 13.29; found: C 53.31, H 43.59, N 13.30. 
 
4.3.10. Ethyl 2-cyano-2-(4-oxo-3-phenyl-1,3-selenazolidin-2-ylidene)acetate (13k). Yield: 236 mg 
(64%). Brownish crystals. Mp 189–191 °C. IR: 2982w, 2936w, 2206s, 1739s, 1679s, 1595w, 1511s, 
1496s, 1367w, 1355m, 1290s, 1210s, 1176s, 1167s, 1119s, 1016w, 846w, 768w, 696m. 1H-NMR: 1.31 
(t, J = 7.2, CH3), 3.83 (s, CH2), 4.29 (q, J = 7.1, CH2O), 7.26 (d, J ≈ 8.2, 2 arom. H), 7.52–7.62 (m, 3 
arom. H). 13C-NMR: 14.1 (CH3), 24.2 (CH2), 62.2 (CH2), 81.4 (C(CN)), 111.7 (CN), 128.7 (2 CH), 
129.8 (2 CH), 131.0 (CH), 135.8 (Car), 166.4, 168.1 (CO, CO2), 174.6 (CNSe). CI-MS: 354 (100, 
[M(80Se)+NH4]+). Anal. calcd for C14H12N2O3Se (335.22): C 50.16, H 3.61, N 8.36; found: C 50.01, H 
3.93, N 8.04. 
Suitable crystals for the X-ray crystal structure determination were grown from CH2Cl2 by slow 
evaporation of the solvent. 
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4.3.11. Ethyl 2-[3-(4-bromophenyl)-4-oxo-1,3-selenazolidin-2-ylidene]-2-cyanoacetate (13l). Yield: 
392 mg  (86%). Pale yellow crystals. Mp 191–193 °C. IR: 2984w, 2206s, 1743s, 1678s, 1509s, 1498s, 
1486s, 1360m, 1292s, 1210m, 1176s, 1165s, 1129m, 1066w, 1013m, 845w, 834w, 821w, 770w, 714w. 
1H-NMR: 1.31 (t, J = 7.2, CH3), 3.81 (s, CH2), 4.29 (q, J = 7.1, CH2O), 7.12, 7.67 (AA'BB', JAB ≈ 8.3, 4 
arom. H). 13C-NMR: 14.0 (CH3), 24.1 (CH2), 62.3 (CH2), 81.6 (C(CN)), 111.9 (CN), 125.3 (Car), 130.3 
(2 CH), 133.1 (2 CH), 134.7 (Car), 166.2, 167.4 (CO, CO2), 174.3 (CNSe). CI-MS: 434 (80, [M(80Se, 
81Br)+NH4]+), 432 (100, [M(80Se, 79Br)+NH4]+). Anal. calcd for C14H11N2O3SeBr (414.12): C 40.60, H 
2.68, N 6.76; found: C 40.71, H 2.91, N 6.68. 
 
4.3.12. Ethyl 2-cyano-2-[4-oxo-3-(4-methylphenyl)-1,3-selenazolidin-2-ylidene)acetate (13m). Yield: 
300 mg (78%). Pale yellow crystals. Mp 187–189 °C. IR: 2982w, 2930w, 2204s, 1740s, 1679s, 1505s, 
1359m, 1291m, 1211s, 1180s, 1169s, 1117m, 1016w, 846w, 770w, 716w. 1H-NMR: 1.30 (t, J = 7.2, 
CH3), 2.44 (s, CH3), 3.81 (s, CH2), 4.28 (q, J = 7.1, CH2O), 7.12, 7.33 (AA'BB', JAB ≈ 8.3, 4 arom. H). 
13C-NMR: 14.0 (CH3), 21.4 (CH3), 24.2 (CH2), 62.2 (CH2), 81.3 (C(CN)), 111.8 (CN), 128.4 (2 CH), 
130.5 (2 CH), 133.1 (Car), 141.3 (Car), 166.5, 168.4 (CO, CO2), 174.7 (CNSe). CI-MS: 368 (100, 
[M(80Se)+NH4]+). Anal. calcd for C15H14N2O3Se (349.25): C 51.59, H 4.04, N 8.02; found: C 52.06, H 
4.38, N 7.94. 
 
4.4. X-Ray crystal-structure determination of 10a, 10c, 13a, and 13k  
 
All measurements were performed on a Nonius KappaCCD area-diffractometer47 using graphite-
monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 cooler. The 
data collection and refinement parameters are given below48 and views of the molecules are shown in 
Figures 1–3. Data reduction was performed with HKL Denzo and Scalepack.49 The intensities were 
corrected for Lorentz and polarization effects, and absorption corrections based on the multi-scan 
method50 were applied. Equivalent reflections, other than the Friedel pairs in 13a, were merged. The 
structures were  solved by direct methods using SIR92,51 which revealed the positions of all non-H-
atoms. In the case of 10a, the two CH2 groups in the five-membered ring are disordered over two 
conformations. Two sets of positions were defined for the atoms of these groups and the site occupation 
factor of the major conformation refined to 0.51(1). Similarity restraints were applied to the chemically 
equivalent bond lengths and angles involving all disordered C-atoms. In the case of 13k, there are two 
symmetry-independent molecules in the asymmetric unit. The atomic coordinates of the two molecules 
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were tested carefully for a relationship from a higher symmetry space group using the program 
PLATON,52 but none could be found. The terminal ethyl group in one molecule is disordered over two 
conformations. Two sets of overlapping positions were defined for the atoms of this group and the site 
occupation factor of the major conformation of this group refined to 0.58(2). Similarity restraints were 
applied to the chemically equivalent bond lengths and angles involving all disordered C-atoms, while 
neighboring atoms within and between each conformation of the disordered ethyl group were restrained 
to have similar atomic displacement parameters. The non-H-atoms were refined anisotropically. All of 
the H-atoms were placed in geometrically calculated positions and refined using a riding model where 
each H-atom was assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq of its 
parent C-atom (1.5Ueq for the methyl groups). The refinement of the structures was carried out on F2 
using full-matrix least-squares procedures, which minimized the function Σw(Fo2 – Fc2)2. Corrections for 
secondary extinction were applied in the cases of 10c, 13a, and 13k. In 10a and in 10c, one reflection, 
whose intensity was considered to be an extreme outlier, was omitted from the final refinement. 
Refinement of the absolute structure parameter53 of 13a yielded a value of –0.021(7), which confidently 
confirms that the refined coordinates represent the true absolute structure. Neutral atom scattering 
factors for non-H-atoms were taken from54, and the scattering factors for H-atoms were taken from ref.55 
Anomalous dispersion effects were included in Fc;56 the values for f' and f" were those of ref.57 The 
values of the mass attenuation coefficients are those of ref.58 All calculations were performed using the 
SHELXL9759 program. 
 
Crystal data for 10a: C12H9N3Se, M = 274.12, pale-yellow, prism, crystal dimensions 0.07 × 0.12 × 0.20 
mm, monoclinic, space group P21/c, Z = 4, reflections for cell determination 22243, 2θ range for cell 
determination 4 – 60°, a = 7.5986(1) Å, b = 16.6005(3) Å, c = 8.8620(1) Å, β = 94.199(1)°, V = 
1114.86(3) Å3, T = 160 K, DX = 1.633 g⋅cm–3, µ(MoKα) = 3.339 mm–1, scan type φ and ω, 2θ(max) = 60°, 
transmission factors (min; max) 0.542; 0.792, total reflections measured 33680, symmetry independent 
reflections 3253, reflections with I > 2σ(I) 2814, reflections used in refinement 3252, parameters refined 
164; restraints 3, R(F) [I > 2σ(I) reflections] = 0.0267, wR(F2) [all data] = 0.0647 (w = [σ2(Fo2)+ 
(0.0275P)2+0.5667P]–1, where P = (Fo2+2Fc2)/3), goodness of fit 1.058, final ∆max/σ 0.001, ∆ρ (max; 
min) = 0.41; –0.73 e Å–3. 
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Crystal data for 10c: C13H11N3OSe, M = 304.15, pale-yellow, prism, crystal dimensions 0.10 × 0.23 × 
0.28 mm, triclinic, space group P
_
,1, Z = 2, reflections for cell determination 13000, 2θ range for cell 
determination 4 – 60°, a = 8.4715(2) Å, b = 8.6795(2) Å, c = 8.8012(2) Å, α = 98.756(2), β = 
91.399(2)°, γ = 100.280(1), V = 628.44(3) Å3, T = 160 K, DX = 1.607 g⋅cm–3, µ(MoKα) = 2.976 mm–1, 
scan type φ and ω, 2θ(max) = 60°, transmission factors (min; max) 0.489; 0.751, total reflections 
measured 18210, symmetry independent reflections 3671, reflections with I > 2σ(I) 3252, reflections 
used in refinement 3670, parameters refined 165; R(F) [I > 2σ(I) reflections] = 0.0326, wR(F2) [all data] 
= 0.0838 (w = [σ2(Fo2)+ (0.0458P)2+0.1693P]–1, where P = (Fo2+2Fc2)/3), goodness of fit 1.058, 
secondary extinction coefficient 0.012(2), final ∆max/σ 0.001, ∆ρ (max; min) = 0.74; –0.95 e Å–3. 
 
Crystal data for 13a: C12H7N3OSe, M = 288.11, colorless, needle, crystal dimensions 0.10 × 0.10 × 0.28 
mm, monoclinic, space group Cc, Z = 4, reflections for cell determination 9429, 2θ range for cell 
determination 4 – 60°, a =17.0737(4) Å, b = 9.5587(2) Å, c = 7.0931(2) Å, β = 104.623(1)°, V = 
1120.11(5) Å3, T = 160 K, DX = 1.708 g⋅cm–3, µ(MoKα) = 3.335 mm–1, scan type φ and ω, 2θ(max) = 60°, 
transmission factors (min; max) 0.508; 0.723, total reflections measured 14521, symmetry independent 
reflections 3197, reflections with I > 2σ(I) 3084, reflections used in refinement 3197, parameters refined 
155; restraints 2, R(F) [I > 2σ(I) reflections] = 0.0236, wR(F2) [all data] = 0.0544 (w = [σ2(Fo2)+ 
(0.0253P)2+0.7032P]–1, where P = (Fo2+2Fc2)/3), goodness of fit 1.046, secondary extinction coefficient 
0.0064(5), final ∆max/σ 0.001, ∆ρ (max; min) = 0.30; –0.46 e Å–3. 
 
Crystal data for 13k: C14H12N2O3Se, M = 335.16, yellow, prism, crystal dimensions 0.10 × 0.22 × 0.25 
mm, monoclinic, space group P21/c, Z = 8, reflections for cell determination 89915, 2θ range for cell 
determination 4 – 55°, a =9.6396(1) Å, b = 12.9321(2) Å, c = 21.8547(3) Å, β = 94.4025(8)°, V = 
2716.37(6) Å3, T = 160 K, DX = 1.639 g⋅cm–3, µ(MoKα) = 2.771 mm–1, scan type φ and ω, 2θ(max) = 55°, 
transmission factors (min; max) 0.590; 0.761, total reflections measured 55029, symmetry independent 
reflections 6222, reflections with I > 2σ(I) 5276, reflections used in refinement 6222, parameters refined 
384; restraints 39, R(F) [I > 2σ(I) reflections] = 0.0305, wR(F2) [all data] = 0.0712 (w = [σ2(Fo2)+ 
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(0.0288P)2+2.26P]–1, where P = (Fo2+2Fc2)/3), goodness of fit 1.046, secondary extinction coefficient 
0.0012(2), final ∆max/σ 0.001, ∆ρ (max; min) = 0.60; –0.49 e Å–3. 
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